Peter Buhler - Valneva SE Chief Officer
| VALN Stock | USD 7.25 0.52 7.73% |
Executive
Peter Buhler is Chief Officer of Valneva SE ADR
| Age | 54 |
| Address | 6 rue Alain Bombard, Saint-Herblain, France, 44800 |
| Phone | 33 2 28 07 37 10 |
| Web | https://valneva.com |
Valneva SE Management Efficiency
The company has return on total asset (ROA) of (0.1059) % which means that it has lost $0.1059 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0396) %, meaning that it created substantial loss on money invested by shareholders. Valneva SE's management efficiency ratios could be used to measure how well Valneva SE manages its routine affairs as well as how well it operates its assets and liabilities. As of the 21st of March 2025, Return On Tangible Assets is likely to drop to -0.28. In addition to that, Return On Capital Employed is likely to grow to -0.3. At this time, Valneva SE's Debt To Assets are very stable compared to the past year. As of the 21st of March 2025, Fixed Asset Turnover is likely to grow to 1.01, though Other Assets are likely to grow to (10.2 M).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Brendan Eckelman | Inhibrx | 46 | |
| Theresa Bruce | NuCana PLC | N/A | |
| Anand Sundaram | Opthea | N/A | |
| Ali JD | Tyra Biosciences | N/A | |
| Steven Sweeney | Third Harmonic Bio | N/A | |
| Huw Nash | Stoke Therapeutics | 57 | |
| Edmund Dunn | Monte Rosa Therapeutics | 59 | |
| Aaron MD | Sage Therapeutic | N/A | |
| Sarah Foster | Mineralys Therapeutics, Common | N/A | |
| Mr MBA | C4 Therapeutics | 46 | |
| Carlos Bais | Inhibrx | N/A | |
| Douglas MD | Tyra Biosciences | 53 | |
| MBA MD | Sellas Life Sciences | 62 | |
| Daniel George | Anebulo Pharmaceuticals | 55 | |
| Laura MD | Sage Therapeutic | 55 | |
| Martin Quinn | NuCana PLC | N/A | |
| Philippe Sauvage | Nuvation Bio | 48 | |
| Isabel Chiu | C4 Therapeutics | N/A | |
| Mary Fenton | Cullinan Oncology LLC | 60 | |
| Helen Colquhoun | Sage Therapeutic | N/A | |
| Maren Killackey | Sage Therapeutic | N/A | |
Management Performance
| Return On Equity | -0.0396 | ||||
| Return On Asset | -0.11 |
Valneva SE ADR Leadership Team
Elected by the shareholders, the Valneva SE's board of directors comprises two types of representatives: Valneva SE inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Valneva. The board's role is to monitor Valneva SE's management team and ensure that shareholders' interests are well served. Valneva SE's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Valneva SE's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Vincent Dequenne, Chief Officer | ||
| Frederic Jacotot, General IP | ||
| JuanCarlos MD, Chief Officer | ||
| Thomas Lingelbach, CEO President | ||
| Gerald Strohmaier, VP Resource | ||
| Peter Buhler, Chief Officer | ||
| Christian Taucher, Head Affairs | ||
| Perry Celentano, Interim Officer | ||
| Joshua Drumm, Vice Relations | ||
| Dipal Patel, Chief Officer | ||
| Susanne EderLingelbach, Head Operations | ||
| Laetitia BachelotFontaine, VP Relations | ||
| Petra Pesendorfer, Chief Officer | ||
| Katrin Dubischar, VP Vaccine | ||
| Franck MBA, Chief Officer | ||
| Hanneke Schuitemaker, Chief Officer |
Valneva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Valneva SE a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0396 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.05) % | ||||
| Operating Margin | (0.27) % | ||||
| Current Valuation | 646.44 M | ||||
| Shares Outstanding | 81.2 M | ||||
| Shares Owned By Institutions | 1.01 % | ||||
| Number Of Shares Shorted | 36.65 K | ||||
| Price To Book | 2.48 X | ||||
| Price To Sales | 3.71 X |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Valneva SE ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Valneva SE. If investors know Valneva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Valneva SE listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.13) | Revenue Per Share | Quarterly Revenue Growth 0.204 | Return On Assets | Return On Equity |
The market value of Valneva SE ADR is measured differently than its book value, which is the value of Valneva that is recorded on the company's balance sheet. Investors also form their own opinion of Valneva SE's value that differs from its market value or its book value, called intrinsic value, which is Valneva SE's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Valneva SE's market value can be influenced by many factors that don't directly affect Valneva SE's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Valneva SE's value and its price as these two are different measures arrived at by different means. Investors typically determine if Valneva SE is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Valneva SE's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.